

Clinical Trial Protocol

Iranian Registry of Clinical Trials

14 Jun 2026

Intrauterine delivery of Dexamethasone for repeated implantation failure: a RCT

Protocol summary

Study aim

Increased pregnancy and childbirth lead to the birth of a live baby in patients with recurrent implantation failure.

Design

Clinical trial with control group, with parallel groups, single blind, randomized, on 60 patients. The randomization function of the Excel software was used for randomization.

Settings and conduct

A questionnaire is completed for patients who meet the criteria for admission to the study and after obtaining informed consent. According to the random list, patients are divided into intervention and control groups. In both groups, after baseline ultrasound on the second day of the cycle, the ART cycle begins. In interventional patients on days 9 and 12 of intrauterine injection of dexamethasone 600µL (5 mg / ml) The fetus is transferred slowly with a fetal catheter. In patients with the control group, the same normal volume of sterile saline is prescribed.

Participants/Inclusion and exclusion criteria

This study is clinical trial of patients with recurrent idiopathic implantation failure. Patients with at least twice a history of ART and having a total of six transplanted grade one embryos if they have the criteria to enter the study after obtaining informed consent. Criteria for entering the study: • Minor age 40 years • Proper ovarian storage (AMH) above one • At least twice the previous ART by transferring at least six first-degree embryos • Healthy uterine cavity in ultrasound and hysteroscopy (absence of uterine anomaly, endometrial polyp, uterine myoma) • Absence of endocrinopathy and autoimmune and thrombophilic disease • Normal karyotype

Intervention groups

According to the random list, patients are divided into intervention and control groups.

Main outcome variables

Endometrial thickness, implantation, pregnancy (βHCG-

positive-clinical pregnancy), live birth, miscarriage, ectopic pregnancy

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200502047261N1**

Registration date: **2023-02-20, 1401/12/01**

Registration timing: **retrospective**

Last update: **2023-02-20, 1401/12/01**

Update count: **0**

Registration date

2023-02-20, 1401/12/01

Registrant information

Name

zahara sadat khonsarian

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 2296 7790

Email address

hsn.khosropour@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-05-22, 1398/03/01

Expected recruitment end date

2020-03-19, 1398/12/29

Actual recruitment start date

2019-05-31, 1398/03/10

Actual recruitment end date

2020-03-19, 1398/12/29

Trial completion date

2020-03-19, 1398/12/29

Scientific title

Intrauterine delivery of Dexamethasone for repeated implantation failure: a RCT

Public title

Intrauterine delivery of Dexamethasone for repeated implantation failure: a RCT

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Age under 40 years (AMH) above one At least twice the previous ART by transferring at least six grade one embryos Healthy uterine cavity in ultrasound and hysteroscopy (lack of uterine anomaly, endometrial polyp, uterine myoma) Absence of endocrinopathy and autoimmune and thrombophilic diseases Normal karyotype Absence of severe male infertility Absence of moderate or severe endometriosis Absence of a specific cause for implantation in previous ARTs Absence of hydrosalpinx

Exclusion criteria:

Age over 40 years (AMH) below one Abnormal uterine cavities on ultrasound and hysteroscopy (with uterine anomalies, endometrial polyps, uterine myomas) Endocrinopathy and autoimmune and thrombophilic diseases Abnormal karyotype Severe male infertility Existence of a specific cause of non-implantation in previous ARTs Existence of hydrosalpinx Severe or moderate endometriosis

Age

To 40 years old

Gender

Female

Phase

N/A

Groups that have been masked

- Participant

Sample size

Target sample size: 60

Actual sample size reached: 60

Randomization (investigator's opinion)

Randomized

Randomization description

Based on random sampling, patients are divided into intervention and control groups.

Blinding (investigator's opinion)

Single blinded

Blinding description

For patients who have the criteria to enter the study, after obtaining informed consent, according to the decision of the ethics committee of Tehran University of Medical Sciences, a questionnaire will be completed and they are unaware of the allocation of the study group.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committee in Research, School of Medicine, Tehran University of Medical Sciences

Street address

headquarters of Tehran University of Medical Sciences, Intersection of Keshavarz Boulevard and Quds Street

City

Tehran

Province

Tehran

Postal code

141765376

Approval date

2019-05-13, 1398/02/23

Ethics committee reference number

IR.TUMS.MEDICINE.REC.1398.084

Health conditions studied**1****Description of health condition studied**

Patients with repeated implantation failure

ICD-10 code**ICD-10 code description****Primary outcomes****1****Description**

Pregnancy

Timepoint

According to the random list, patients are divided into intervention and control groups. In both groups, after basic ultrasound on the second day of the cycle, the ART cycle begins, and ovarian stimulation information is recorded for each patient. In patients in the 9 and 12 days of intramuscular injection of dexamethasone 600µL (5mg / ml) with a fetal transfer catheter, the intervention is performed slowly. In patients with the control group, the same normal volume of sterile saline is prescribed. Both groups are followed by transvaginal ultrasound while taking ART. When at least two follicles are seen, 10,000 HCG units are injected and 36 hours later the pancreas is transplanted under vaginal ultrasound. The ultrasound is performed two weeks later and the pregnancy sac is examined.

Method of measurement

Pregnancy test(βHCG)

Secondary outcomes

empty

Intervention groups

1

Description

Control group: In the control group, on days 9 and 12, normal intrauterine injection of 600µL sterile saline (5 mg / ml) is performed with a fetal transfer catheter.

Category

Placebo

2

Description

Intervention group: In patients in the 9 and 12 days of intramuscular injection of dexamethasone 600µL (5 mg / ml) with a fetal transfer catheter.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Shariati hospital

Full name of responsible person

Saeid Mehrpour

Street address

Jalal-e-Al-e-Ahmad Hwy

City

Tehran

Province

Tehran

Postal code

1411713135

Phone

+98 21 8490 1000

Fax

+98 21 8863 3039

Email

shariatihosp@tums.ac.ir

Web page address

<http://shariati.tums.ac.ir/>

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

shahin akhoundzade

Street address

Intersection of Keshavarz Boulevard and Quds Street, headquarters of Tehran University of Medical

Sciences

City

Tehran

Province

Tehran

Postal code

141765376

Phone

+98 21 6640 5357

Fax

+98 21 8895 3003

Email

deanmed@tums.ac.ir

Web page address

<http://medicine.tums.ac.ir/college>

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Tehran University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Zahra sadat Khonsarian

Position

Resident

Latest degree

Medical doctor

Other areas of specialty/work

Gynecology and Obstetrics

Street address

No.13, Nahid Ave, Vafamanesh Ave., Heravi Sq

City

Tehran

Province

Tehran

Postal code

1668756738

Phone

+98 21 2296 7790

Email

hsn.khosropour@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Zahra sadat Khonsarian

Position

Resident

Latest degree

Medical doctor

Other areas of specialty/work

Gynecology and Obstetrics

Street address

No.13, Nahid Ave., Vafamanesh Ave., Heravi Sq

City

Tehran

Province

Tehran

Postal code

1668756738

Phone

+98 21 2296 7790

Email

hsn.khosropour@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Zahra sadat Khonsarian

Position

Resident

Latest degree

Medical doctor

Other areas of specialty/work

Gynecology and Obstetrics

Street address

No.13, Nahid Ave, Vafamanesh Ave, Heravi Sq

City

Tehran

Province

Tehran

Postal code

1668756738

Phone

+98 21 2296 7790

Email

hsn.khosropour@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available